3,4-dihydroxybenzohydroxamic acid has been researched along with Medulloblastoma in 1 studies
Medulloblastoma: A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horvath, Z | 1 |
| Höchtl, T | 1 |
| Bauer, W | 1 |
| Fritzer-Szekeres, M | 1 |
| Elford, HL | 1 |
| Szekeres, T | 1 |
| Tihan, T | 1 |
1 other study available for 3,4-dihydroxybenzohydroxamic acid and Medulloblastoma
| Article | Year |
|---|---|
Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cere | 2004 |